Resume
SRIVIDYA MYNENI
M.S Pharm Sciences
------------
------------
A highly motivated scientific researcher experienced in developing, optimizing and executing bio chemical and cellular assays in translating biologics from early discovery to clinical development
TECHNICAL SKILLS
• Functional assays with primary immune cells (Macrophages, Dendritic cells, B and T cells)
• Immune cell isolation from whole blood (Ficoll,MACS, RosetteSep, etc).
• Extensive experience in multicolor flow cytometry (8+colors)
• Mammalian, murine and bacterial cell culture techniques
• Development of novel antibodies through Hybridoma technology
• Enzyme-linked immunosorbent assay (ELISA) development and validation
• Designing polymerase chain reaction(PCR) for amplification of a target gene
• DNA, RNA isolation and Transfection
• Fast protein liquid chromatography (FPLC, Bio-Rad)
• Agarose gel electrophoresis, SDS-PAGE and Western blotting
• Proficient in FlowJo, Spotfire, GraphPad/Prism, and R/R-Studio
EDUCATION
Master’s in Pharmaceutical Sciences (M.S)
University at Buffalo, U.S.A (Aug 2015-September 2017)
Bachelor’s in Pharmaceutical Sciences (B.S)
Birla Institute of Technology and Science-Pilani, India (Aug 2011-May 2015)
RESEARCH EXPERIENCE
Genentech, Inc. U.S.A Oct 2017 – Present
Role: Scientific Researcher(Intern), Bioanalytical Sciences Department
• Evaluated the immunogenicity potential of various biotherapeutics using human in-vitro assays: Monocyte-derived dendritic cells (DCs) from healthy donors are exposed in vitro to biotherapeutic proteins. T cells are co-cultured with drug exposed DCs and T-cell proliferation is measured using a flow cytometry based assay. T cell response rates are used to evaluate the immunogenicity of biotherapeutics
• Developed a novel method to accurately quantify ADCP activity of various antibody therapeutics: A quantitative flow cytometry based method is developed to quantify ADCP activity of antibody therapeutics in which target cells are labeled with pH sensitive dye and fluorescence of internalized cells is used as a readout for phagocytosis. The assay format is able to distinguish glycovariants which makes it as useful tool for lead candidate selection
• Developed a cell based assay to measure bispecific antibody dependent cellular synapse: An in vitro flow cytometry based assay is established using an early marker of T cell activation as a surrogate for cellular synapse formation. Data derived from the assay is used to develop a mechanism-based model to assess the effect of various factors on cellular synapse formation
• Developed kinetic ADCC assay as an alternative to endpoint ADCC assay: A live cell imaging system which automatically detects and counts individual cells is used to quantify cell lysis in real time. The shortened assay time coupled with comparable sensitivity to end point ADCC assay makes the kinetic ADCC assay a valid alternative for measuring in vitro ADCC activity of mAbs.
Takeda Pharmaceuticals U.S.A., Inc. May 2016-Sep 2016
Role: Intern in Modeling and Simulation, Quantitative Pharmacology Department
Using modeling and simulation for preclinical to clinical translation of nanoparticles: Developed suitable compartmental models to simulate the concentration-time profile over a given period of time for the drug in a nanoparticle and conventional formulation. The effect of dose and dosing regimen on efficacy and toxicity of nanoparticle formulation was analyzed.
University at Buffalo, NY. Aug 2015 – July 2017
• Development of anti-LRP1 (Lipoprotein Receptor related Protein) monoclonal antibody using hybridoma technology: A stable hybridoma cell line was established by fusing mouse splenocytes with mouse myeloma cells. ELISA based method was developed to screen the positive hybridoma cells. Fast protein liquid chromatography was utilized to purify monoclonal antibodies from hybridoma cell supernatant. Western blot, flow cytometry and isotyping were performed to determine the specificity and isotype of antibodies. The monoclonal antibody was conjugated to a cytotoxic drug and in-vitro cytotoxicity was measured using a cell based assay.
• Construction of a platform expression plasmid for chimerization of murine monoclonal antibodies: Platform expression plasmid was developed by cloning human IgG constant regions of heavy and light chains and an extra promoter and termination gene into commercially available plasmid using E.coli system. Validation of plasmid was performed by expressing full length human IgG in CHO cells. The recombinant IgG antibody was purified from CHO cell supernatant using fast protein liquid chromatography.
Birla Institute of Technology and Science-Pilani, India Aug 2014-May 2015
• Effect of esterase modulators and P-gp inhibitors on intestinal permeability of anti-HIV prodrug Tenofovir Disoproxil Fumarate: An ex vivo everted gut sac model was used to evaluate the absorption enhancement of the pro drug and metabolites in wistar rats in the presence of various esterase modulators and P-gp inhibitors. HPLC based method was developed to determine the concentration of drug and its metabolites inside and outside the gut to measure the intestinal absorption.
PUBLICATIONS & POSTER PRESENTATIONS
• A novel method for determining antibody-dependent cellular phagocytosis. Journal of immunological methods (2019), 468, pp.55-60.
• Development of a kinetic antibody-dependent cellular cytotoxicity assay. Journal of immunological methods468 (2019): 49-54.
• Tenofovir disoproxil fumarate loaded PLGA nanoparticles for enhanced oral absorption: Effect of experimental variables and in vitro, ex vivo and in vivo evaluation. Colloids and Surfaces B: Biointerfaces 158 (2017): 610-619.
• Oral pharmacokinetic interaction of ester rich fruit juices and pharmaceutical excipients with tenofovir disoproxil fumarate in male Wistar rats. Xenobiotica (2017): 1-8.
• Curcumin delivery by poly (Lactide)-based co-polymeric micelles: an in vitro anticancer study. Pharmaceutical research 33, no. 4 (2016): 826-841.
• Won second prize in 66th Indian Pharmaceutical Congress for the poster entitled “Effect of Pharmaceutical excipients on intestinal permeability of ester prodrug Tenofovir Disoproxil Fumarate.”
SRIVIDYA MYNENI
M.S Pharm Sciences
------------
------------
A highly motivated scientific researcher experienced in developing, optimizing and executing bio chemical and cellular assays in translating biologics from early discovery to clinical development
TECHNICAL SKILLS
• Functional assays with primary immune cells (Macrophages, Dendritic cells, B and T cells)
• Immune cell isolation from whole blood (Ficoll,MACS, RosetteSep, etc).
• Extensive experience in multicolor flow cytometry (8+colors)
• Mammalian, murine and bacterial cell culture techniques
• Development of novel antibodies through Hybridoma technology
• Enzyme-linked immunosorbent assay (ELISA) development and validation
• Designing polymerase chain reaction(PCR) for amplification of a target gene
• DNA, RNA isolation and Transfection
• Fast protein liquid chromatography (FPLC, Bio-Rad)
• Agarose gel electrophoresis, SDS-PAGE and Western blotting
• Proficient in FlowJo, Spotfire, GraphPad/Prism, and R/R-Studio
EDUCATION
Master’s in Pharmaceutical Sciences (M.S)
University at Buffalo, U.S.A (Aug 2015-September 2017)
Bachelor’s in Pharmaceutical Sciences (B.S)
Birla Institute of Technology and Science-Pilani, India (Aug 2011-May 2015)
RESEARCH EXPERIENCE
Genentech, Inc. U.S.A Oct 2017 – Present
Role: Scientific Researcher(Intern), Bioanalytical Sciences Department
• Evaluated the immunogenicity potential of various biotherapeutics using human in-vitro assays: Monocyte-derived dendritic cells (DCs) from healthy donors are exposed in vitro to biotherapeutic proteins. T cells are co-cultured with drug exposed DCs and T-cell proliferation is measured using a flow cytometry based assay. T cell response rates are used to evaluate the immunogenicity of biotherapeutics
• Developed a novel method to accurately quantify ADCP activity of various antibody therapeutics: A quantitative flow cytometry based method is developed to quantify ADCP activity of antibody therapeutics in which target cells are labeled with pH sensitive dye and fluorescence of internalized cells is used as a readout for phagocytosis. The assay format is able to distinguish glycovariants which makes it as useful tool for lead candidate selection
• Developed a cell based assay to measure bispecific antibody dependent cellular synapse: An in vitro flow cytometry based assay is established using an early marker of T cell activation as a surrogate for cellular synapse formation. Data derived from the assay is used to develop a mechanism-based model to assess the effect of various factors on cellular synapse formation
• Developed kinetic ADCC assay as an alternative to endpoint ADCC assay: A live cell imaging system which automatically detects and counts individual cells is used to quantify cell lysis in real time. The shortened assay time coupled with comparable sensitivity to end point ADCC assay makes the kinetic ADCC assay a valid alternative for measuring in vitro ADCC activity of mAbs.
Takeda Pharmaceuticals U.S.A., Inc. May 2016-Sep 2016
Role: Intern in Modeling and Simulation, Quantitative Pharmacology Department
Using modeling and simulation for preclinical to clinical translation of nanoparticles: Developed suitable compartmental models to simulate the concentration-time profile over a given period of time for the drug in a nanoparticle and conventional formulation. The effect of dose and dosing regimen on efficacy and toxicity of nanoparticle formulation was analyzed.
University at Buffalo, NY. Aug 2015 – July 2017
• Development of anti-LRP1 (Lipoprotein Receptor related Protein) monoclonal antibody using hybridoma technology: A stable hybridoma cell line was established by fusing mouse splenocytes with mouse myeloma cells. ELISA based method was developed to screen the positive hybridoma cells. Fast protein liquid chromatography was utilized to purify monoclonal antibodies from hybridoma cell supernatant. Western blot, flow cytometry and isotyping were performed to determine the specificity and isotype of antibodies. The monoclonal antibody was conjugated to a cytotoxic drug and in-vitro cytotoxicity was measured using a cell based assay.
• Construction of a platform expression plasmid for chimerization of murine monoclonal antibodies: Platform expression plasmid was developed by cloning human IgG constant regions of heavy and light chains and an extra promoter and termination gene into commercially available plasmid using E.coli system. Validation of plasmid was performed by expressing full length human IgG in CHO cells. The recombinant IgG antibody was purified from CHO cell supernatant using fast protein liquid chromatography.
Birla Institute of Technology and Science-Pilani, India Aug 2014-May 2015
• Effect of esterase modulators and P-gp inhibitors on intestinal permeability of anti-HIV prodrug Tenofovir Disoproxil Fumarate: An ex vivo everted gut sac model was used to evaluate the absorption enhancement of the pro drug and metabolites in wistar rats in the presence of various esterase modulators and P-gp inhibitors. HPLC based method was developed to determine the concentration of drug and its metabolites inside and outside the gut to measure the intestinal absorption.
PUBLICATIONS & POSTER PRESENTATIONS
• A novel method for determining antibody-dependent cellular phagocytosis. Journal of immunological methods (2019), 468, pp.55-60.
• Development of a kinetic antibody-dependent cellular cytotoxicity assay. Journal of immunological methods468 (2019): 49-54.
• Tenofovir disoproxil fumarate loaded PLGA nanoparticles for enhanced oral absorption: Effect of experimental variables and in vitro, ex vivo and in vivo evaluation. Colloids and Surfaces B: Biointerfaces 158 (2017): 610-619.
• Oral pharmacokinetic interaction of ester rich fruit juices and pharmaceutical excipients with tenofovir disoproxil fumarate in male Wistar rats. Xenobiotica (2017): 1-8.
• Curcumin delivery by poly (Lactide)-based co-polymeric micelles: an in vitro anticancer study. Pharmaceutical research 33, no. 4 (2016): 826-841.
• Won second prize in 66th Indian Pharmaceutical Congress for the poster entitled “Effect of Pharmaceutical excipients on intestinal permeability of ester prodrug Tenofovir Disoproxil Fumarate.”